Our lab is equipped with a collection of state of the art instruments to enable miniaturization and automation of a variety of biological assays. The automated system is comprised of:
High Content Screening (HCS) Platform, which is an automated cellular imaging and analysis platform designed for quantitative microscopy.
- Flow Cytometry, which enables multi-parametric single cell analysis.
- Automated workstation, for liquid handling for dispensing accurate and reproducible volumes of liquids and compounds.
- Multimode microplate reader designed for fast measurements of numerous biological reactions/processes.
Readouts generated from these instruments provide us with insights to the effect of our cannabinoid library on parameters such as, proliferation inhibition, apoptosis induction, angiogenesis and toxicity on cancerous cells.
High Throughput Screening
The HTS platform allows us to test many compounds on cancerous cell lines and tissues and measure the therapeutics effects of these compounds.
Our advantage is in the specialized library which is composed of a collection of cannabis extracts and pure natural and synthetic cannabinoids. The library will also include a costumed cannabinoid matrix, to assess the possible interaction of combination therapy.
These experiments will produce multiplexed data composed of images of cells, cell specific markers and the extent/signal of the biological response. The biological response will be measured using different concentration of cannabinoids and their combinations, thus determining the most effective cannabinoid treatment for a specific cancer type.
Circulating Tumor Cells
Identifying Circulating Tumor Cells can be regarded as a “Liquid Biopsy of Cancer” method. CTCs can be useful for screening cancer drugs as they may reflect the severity and heterogeneity of primary tumors. CTCs are present in the blood of many patients with solid tumors. Most of these cells, which are thought to be involved in metastasis, die in the circulation, presumably due to the loss of matrix-derived survival signals or circulatory shear stress. The clinical value of CTCs as a biomarker for early cancer detection, diagnosis, prognosis, prediction, stratification, and pharmacodynamics have been widely explored in recent years. However, the clinical utility of current CTC tests is limited mainly due to methodological constraints.
A full cancer genome and transcriptome is present in each individual CTC, therefore these cells represent an interesting source of tumor information where mutations and gene fusions can be found. Many studies have used enumeration of CTCs to predict recurrence or used cancer-derived biomarkers to follow therapy resistance.
We are currently collaborating with SIMFO, a leading CTC lab based in Germany, in doing in-vitro drug sensitivity tests on liquid biopsies, in doing Cannabinoid Sensitivity Test – the test counts the number of live and dead cancer cells after been exposed to cannabinoid compounds such as THC or CBD and their combinations. As in the CTC count, after gaining multiple data sets and merging them with the expanding database; the test could better predict treatment outcome.
Different people respond to different cannabinoids compositions differently.
Cannabics’ vision is to create personalized natural medicine tailored to specific types of cancers and genetics of patients utilizing novel biotechnological tools. The genetic profiling of the individual patient enables us to optimize therapeutic procedures and therapy outcomes.
Data analytics are a key component of the novel platform developed by Cannabics in its efforts to enable practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient’s profile and cancer. We are developing a proprietary platform employs cutting-edge machine learning algorithms and deep learning models to integrate large quantities of multi-omic profile, environment and lifestyle data into a high content drug sensitivity screening pipeline, enabling the development of highly personalized models that practitioners can rely on as preventative, primary and complementary cannabinoid-based treatment options.
We have developed a proprietary capsule, shown to provide long lasting effect of 10-12 hours.
While the medicinal effects of certain cannabinoids are well known to physicians, it is common knowledge that smoking is hazardous to health. Many physicians are perfectly aware of the palliative properties of cannabis (i.e anti-emetic and analgesic), however they refrain from recommending or prescribing it to patients knowing that smoking the raw flowers is still the most common and available administration route. Hence the availability of an oral, standardized, reliable and clinically tested administration route of medical cannabis – no different from the administration route of most medications consumed by patients today – would dramatically improve the availability of medical cannabis therapy to patients in need.
SIMFO GMBH – Bayreuth, Germany
SIMFO GmbH is a research and development facility that has achieved medical renown expertise in personalized medicine. It focuses particularly on the development of innovative analysis methods in oncological diagnostics to optimize patient-specific therapy. SIMFO GmbH supports foreign customers and collaborative partners. SIMFO receives and processes Blood samples from more than 40 countries around the world at the Transfusion Medicine Center in Germany.
Wana Brands – Colorado, United States
Wana Brands has been an innovator in the Colorado infused products industry since 2010. As one of Colorado’s original infused products manufacturers, Wana has developed medicinal products including the state’s most popular sour gummies.
Rambam Medical Center - Israel
Rambam is a world renowned academic hospital acknowledged for their cutting-edge research projects and integration of innovative new therapies and treatments to over 2 million residents of Northern Israel. You can view the details of this ongoing study from the NIH website
While many anecdotal reports by cancer patients using various formulations of Cannabinoids suggest significant efficacy, the lack of pure pharmacologically active compounds and legal restrictions have delayed the clinical research that will ultimately determine the level at which cannabinoids are effective in the treatment of cancer beyond their proven palliative effects. Thus, only few clinical trials have been conducted aiming to confirm the antineoplastic activity of cannabinoids.
Cannabics has successfully conceptualized, funded, executed and concluded two clinical trials, Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome – CACS, and for the Screening of Potential Anticancer Cannabinoid Compounds
Our policy is to seek patent protection for the technology, inventions and improvements that we consider important to the development of our business, but only in those cases where we believe that the costs of obtaining patent protection is justified by the scientific and commercial potential of the technology, and typically only in those jurisdictions that we believe present significant commercial opportunities. We anticipate that we will file additional patent applications in conjunction with our research, testing, and development of our cannabis-based products.